Janney Montgomery Scott LLC Lowers Stake in Moderna, Inc. (NASDAQ:MRNA)

Janney Montgomery Scott LLC lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 21.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,081 shares of the company’s stock after selling 2,686 shares during the period. Janney Montgomery Scott LLC’s holdings in Moderna were worth $419,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Moderna by 32.0% during the second quarter. AQR Capital Management LLC now owns 5,083 shares of the company’s stock worth $604,000 after purchasing an additional 1,232 shares in the last quarter. Mather Group LLC. lifted its stake in shares of Moderna by 25.7% during the third quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after purchasing an additional 262 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its stake in shares of Moderna by 278.2% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,772 shares of the company’s stock worth $185,000 after purchasing an additional 2,039 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Moderna by 164.0% during the third quarter. Exchange Traded Concepts LLC now owns 17,558 shares of the company’s stock worth $1,173,000 after purchasing an additional 10,907 shares in the last quarter. Finally, Willner & Heller LLC acquired a new position in shares of Moderna during the third quarter worth about $488,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MRNA. Morgan Stanley reduced their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Sanford C. Bernstein started coverage on Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. UBS Group cut their price target on Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Wolfe Research started coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and an average target price of $67.26.

Moderna Stock Down 3.0 %

NASDAQ:MRNA opened at $32.60 on Monday. The firm has a market capitalization of $12.55 billion, a PE ratio of -5.60 and a beta of 1.59. The stock has a 50 day moving average of $40.01 and a 200-day moving average of $57.81. Moderna, Inc. has a 52 week low of $31.94 and a 52 week high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.39) earnings per share. Analysts predict that Moderna, Inc. will post -8.95 EPS for the current year.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.